Medpace Holdings, Inc.

MEDP Healthcare Diagnostics & Research

Medpace Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.5 billion, up 20.0% from fiscal 2024.

Revenue
+8.50%
EPS
+24.6%
Free cash flow
−16.6%

Quarter to September 2026, against a year earlier

653.62 18.64 +2.94%
Market cap
$17.8B
P/E
34.6×
Fwd P/E
35.8×
Dividend yield
—
F-score
8/9
Altman Z
8.04
Beneish M
−2.92
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
P/E ratio
34.00 30.45 29.57 35.87

+8 more quarters

P/S ratio
6.14 5.36 5.10 6.40
P/FCF ratio
26.12 21.11 19.21 23.76
P/Operating CF
80.52 92.10 89.99 84.10
P/B ratio
29.81 34.39 22.83 35.29
EV/Sales
5.93 5.22 4.90 6.25
EV/EBITDA
26.55 23.77 22.19 28.09
EV/FCF
25.23 20.56 18.45 23.19
Current Ratio
0.83 0.73 0.85 0.74
Net Debt/EBITDA
(4.10) (3.27) (4.40) (3.10)
Debt/Equity
0.00 0.00 0.00 0.00
Earnings Yield
2.94% 3.28% 3.38% 2.79%
Free Cash Flow Yield
3.83% 4.74% 5.21% 4.21%
Free Cash Flow per Share
7.03 4.90 5.10 6.52
Book value per Share
20.94 15.40 21.03 15.91
Free Cash Flow
196.44 138.10 144.97 188.12
EV/EBIT
27.75 24.90 23.30 29.56
Other line items

Show all line items

Columns are period end dates · fundamentals updated 2 Nov 2026